Meloxicam (CIPLA MELOXICAM 7.5)
What to know about Meloxicam — also sold as CIPLA MELOXICAM 7.5, MELOBIC, APX-Meloxicam, Meloxicam Viatris, MELOXICAM-WGR and 10 more: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.
Meloxicam (brand names: CIPLA MELOXICAM 7.5, MELOBIC, APX-Meloxicam, Meloxicam Viatris, MELOXICAM-WGR and 10 more) is classified as Low risk (1 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. COX-2 selective NSAID with standard NSAID risks but minimal work capacity impairment.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (1 points)
- Recommended maximum duration: 90 days
- PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | PBS listed |
Risk Profile
COX-2 selective NSAID with standard NSAID risks but minimal work capacity impairment.
How Meloxicam is regulated
Meloxicam is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.
United Kingdom NICE / MHRA / FPM
NICE NG59 (Low Back Pain and Sciatica) recommends considering oral NSAIDs for short-term pain management, taking into account risk factors including GI, cardiovascular, and renal risks.
Check this medication against your full medication list
Run a full risk assessment including Meloxicam interactions and compliance checks.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.